Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGXSWX:SDZ -2.32%26 3-Year EPS without NRI Growth Rate is 15.90% as of Jun. 2026, which is at its 10-year median of 15.90. GuruFocus rates XSWX:SDZ with a GF Score™ of 26/100 and a GF Value™ of CHF46.88 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 786 Drug Manufacturers companies, Sandoz Group AG ranks better than 61.2% on this metric.
During the past 12 months, Sandoz Group AG's average EPS without NRI Growth Rate was 19.20% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 15.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of Sandoz Group AG was 15.90% per year. The lowest was 15.90% per year. And the median was 15.90% per year.
Sandoz Group AG (XSWX:SDZ) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Sandoz Group AG 3-Year EPS without NRI Growth Rate Related Terms
XSWX:SDZ vs ZTS, UTHR, VTRS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's 3-Year EPS without NRI Growth Rate falls into.
Sandoz Group AG 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 15.90% mean?
Sandoz Group AG (XSWX:SDZ) has a 3-Year EPS without NRI Growth Rate of 15.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Sandoz Group AG and its competitors. This is near median its historical median of 15.90. Over the past decade, Sandoz Group AG's 3-Year EPS without NRI Growth Rate has ranged from 15.90 to 15.90. According to the industry distribution chart, Sandoz Group AG ranks #305 out of 786 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is Sandoz Group AG's 3-Year EPS without NRI Growth Rate too high?
Sandoz Group AG's current 3-Year EPS without NRI Growth Rate of 15.90% is near median its 10-year median of 15.90. Over the past 10 years, this metric has ranged from a low of 15.90 to a high of 15.90. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.85. Sandoz Group AG's value of 15.90% is 61.4% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #305 out of 786 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's 3-Year EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #305 out of 786 companies for 3-Year EPS without NRI Growth Rate. This puts Sandoz Group AG in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.85. Sandoz Group AG's value of 15.90% is 61.4% above this benchmark. Historically, Sandoz Group AG's own 3-Year EPS without NRI Growth Rate has ranged from 15.90 to 15.90 over the past decade. While the company's 10-year median is 15.90 vs. the industry median of 9.85, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.85, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current 3-Year EPS without NRI Growth Rate of 15.90% is 61.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current 3-Year EPS without NRI Growth Rate is 15.90%, which is near median its own 10-year median of 15.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (XSWX:SDZ) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF46.88, compared to a current price of CHF68.90 — trading 47% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 15.90%, which is near median its 10-year median of 15.90 and 61.4% above the Drug Manufacturers industry median of 9.85. Sandoz Group AG's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current 3-Year EPS without NRI Growth Rate is 15.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandoz Group AG (XSWX:SDZ) Overvalued in 2026?
Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued.
The current stock price of CHF68.90 is trading 47% above its estimated GF Value™ of CHF46.88.
GuruFocus considers Sandoz Group AG to be Significantly Overvalued.
Key valuation signals for XSWX:SDZ:
3-Year EPS without NRI Growth Rate: 15.90% (near median its 10-year median of 15.90)
GF Value™: CHF46.88 vs. price of CHF68.90 (47% above fair value)
Industry Position: 61.4% above the Drug Manufacturers median (#305 of 786)
No single metric tells the full story. See the XSWX:SDZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
26GF Score
Get the complete analysis for XSWX:SDZ
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SDZ has been successfully added to your 
